LCD L36159: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Noridian
Policy LCD-L36159 · Hematology
New genetic testing guidelines for thrombophilia impact billing.
Code intelligence
Policy changes, MAC LCD updates, and CMS guidance matched to code D68.51.
Signal breakdown
10 shown · 10 total in platform
Critical
0%
High
100%
Routine
0%
Low
0%
New this month
+4
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Policy LCD-L36159 · Hematology
New genetic testing guidelines for thrombophilia impact billing.
Policy LCD-L36400 · Hematology
New LCD on genetic testing may impact billing practices.
Policy LCD-L36155 · Hematology
New LCD for genetic testing could impact billing processes.
Policy LCD-DL40238 · Hematology
Impact on billing for hereditary thrombophilia testing.
Policy LCD-DL40242 · Hematology
New LCD for hereditary thrombophilia testing impacts billing.
Policy LCD-DL40274 · Hematology
New LCD requires billing team review.
Policy LCD-L40242 · Clinical Laboratory
Noridian finalizes hereditary thrombophilia genetic test coverage 10/12/2026
Policy LCD-L40274 · Clinical Laboratory
WPS final LCD for hereditary thrombophilia genetic testing, eff. 10/12/2026
Policy LCD-L40259 · Clinical Laboratory
CGS MolDX hereditary thrombophilia genetic testing LCD effective Oct 2026
Policy LCD-L40238 · Clinical Laboratory
Palmetto GBA finalizes hereditary thrombophilia genetic testing coverage Oct 202
Audit documentation
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.